O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications

Shin-Hyuk Kang, Kyung-Jae Park, Chae Yong Kim, Mi Ok Yu, Chul Kee Park, Sung Hye Park, Yong Gu Chung

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

O6-methylguanine-DNA methyltransferase (MGMT) is known as a DNA repair protein, and loss of function in MGMT is related to an increase in survival in patients with malignant gliomas treated with alkylating agents. In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. The MGMT promoter was methylated in six patients. Immunostaining of MGMT was positive in 58.3% of patients. MGMT methylation status was correlated with immunostaining results in five patients (41.7%). The median OS and progression-free survival (PFS) of the whole population were 13.4 months [95% confidence interval (CI), 12.3-14.5 months] and 8.3 months (95% CI, 7.4-9.2 months), respectively. In patients with methylated MGMT promoter, median OS was 15.0 months, compared with 11.3 months in the unmethylated group. Median PFS of gliosarcoma patients was 10.3 months for the methylated group, whereas it was 7.3 months for the unmethylated group. On multivariate analysis, patients with methylated MGMT promoter had better prognosis than patients with unmethylated MGMT promoter with respect to OS and PFS (P = 0.045 and 0.034, respectively). However, there was no statistical significance between MGMT protein expression and survival. The results show that a significant fraction of gliosarcomas have MGMT promoter methylation and protein expression, and suggest that patient survival is associated with MGMT methylation status.

Original languageEnglish
Pages (from-to)477-486
Number of pages10
JournalJournal of Neuro-Oncology
Volume101
Issue number3
DOIs
Publication statusPublished - 2011 Feb 1

Fingerprint

Gliosarcoma
Methyltransferases
Methylation
Immunohistochemistry
DNA
Survival
Disease-Free Survival
Alkylating Agents
DNA Methylation
O-(6)-methylguanine
Protein Methyltransferases
Confidence Intervals
Glioma
DNA Repair
Paraffin

Keywords

  • Gliosarcoma
  • Immunohistochemistry
  • Methylation-specific PCR
  • O -methylguanine-DNA methyltransferase

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. / Kang, Shin-Hyuk; Park, Kyung-Jae; Kim, Chae Yong; Yu, Mi Ok; Park, Chul Kee; Park, Sung Hye; Chung, Yong Gu.

In: Journal of Neuro-Oncology, Vol. 101, No. 3, 01.02.2011, p. 477-486.

Research output: Contribution to journalArticle

@article{01fe3c3cdc1f4acda5b4d0cc8539b756,
title = "O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications",
abstract = "O6-methylguanine-DNA methyltransferase (MGMT) is known as a DNA repair protein, and loss of function in MGMT is related to an increase in survival in patients with malignant gliomas treated with alkylating agents. In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. The MGMT promoter was methylated in six patients. Immunostaining of MGMT was positive in 58.3{\%} of patients. MGMT methylation status was correlated with immunostaining results in five patients (41.7{\%}). The median OS and progression-free survival (PFS) of the whole population were 13.4 months [95{\%} confidence interval (CI), 12.3-14.5 months] and 8.3 months (95{\%} CI, 7.4-9.2 months), respectively. In patients with methylated MGMT promoter, median OS was 15.0 months, compared with 11.3 months in the unmethylated group. Median PFS of gliosarcoma patients was 10.3 months for the methylated group, whereas it was 7.3 months for the unmethylated group. On multivariate analysis, patients with methylated MGMT promoter had better prognosis than patients with unmethylated MGMT promoter with respect to OS and PFS (P = 0.045 and 0.034, respectively). However, there was no statistical significance between MGMT protein expression and survival. The results show that a significant fraction of gliosarcomas have MGMT promoter methylation and protein expression, and suggest that patient survival is associated with MGMT methylation status.",
keywords = "Gliosarcoma, Immunohistochemistry, Methylation-specific PCR, O -methylguanine-DNA methyltransferase",
author = "Shin-Hyuk Kang and Kyung-Jae Park and Kim, {Chae Yong} and Yu, {Mi Ok} and Park, {Chul Kee} and Park, {Sung Hye} and Chung, {Yong Gu}",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s11060-010-0267-9",
language = "English",
volume = "101",
pages = "477--486",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications

AU - Kang, Shin-Hyuk

AU - Park, Kyung-Jae

AU - Kim, Chae Yong

AU - Yu, Mi Ok

AU - Park, Chul Kee

AU - Park, Sung Hye

AU - Chung, Yong Gu

PY - 2011/2/1

Y1 - 2011/2/1

N2 - O6-methylguanine-DNA methyltransferase (MGMT) is known as a DNA repair protein, and loss of function in MGMT is related to an increase in survival in patients with malignant gliomas treated with alkylating agents. In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. The MGMT promoter was methylated in six patients. Immunostaining of MGMT was positive in 58.3% of patients. MGMT methylation status was correlated with immunostaining results in five patients (41.7%). The median OS and progression-free survival (PFS) of the whole population were 13.4 months [95% confidence interval (CI), 12.3-14.5 months] and 8.3 months (95% CI, 7.4-9.2 months), respectively. In patients with methylated MGMT promoter, median OS was 15.0 months, compared with 11.3 months in the unmethylated group. Median PFS of gliosarcoma patients was 10.3 months for the methylated group, whereas it was 7.3 months for the unmethylated group. On multivariate analysis, patients with methylated MGMT promoter had better prognosis than patients with unmethylated MGMT promoter with respect to OS and PFS (P = 0.045 and 0.034, respectively). However, there was no statistical significance between MGMT protein expression and survival. The results show that a significant fraction of gliosarcomas have MGMT promoter methylation and protein expression, and suggest that patient survival is associated with MGMT methylation status.

AB - O6-methylguanine-DNA methyltransferase (MGMT) is known as a DNA repair protein, and loss of function in MGMT is related to an increase in survival in patients with malignant gliomas treated with alkylating agents. In the present study, we determined the status of MGMT using methylation-specific polymerase chain reaction (PCR) and immunohistochemistry on paraffin-embedded specimens in 12 human gliosarcomas, and these results were then related to overall survival (OS) and response to alkylating agents. The MGMT promoter was methylated in six patients. Immunostaining of MGMT was positive in 58.3% of patients. MGMT methylation status was correlated with immunostaining results in five patients (41.7%). The median OS and progression-free survival (PFS) of the whole population were 13.4 months [95% confidence interval (CI), 12.3-14.5 months] and 8.3 months (95% CI, 7.4-9.2 months), respectively. In patients with methylated MGMT promoter, median OS was 15.0 months, compared with 11.3 months in the unmethylated group. Median PFS of gliosarcoma patients was 10.3 months for the methylated group, whereas it was 7.3 months for the unmethylated group. On multivariate analysis, patients with methylated MGMT promoter had better prognosis than patients with unmethylated MGMT promoter with respect to OS and PFS (P = 0.045 and 0.034, respectively). However, there was no statistical significance between MGMT protein expression and survival. The results show that a significant fraction of gliosarcomas have MGMT promoter methylation and protein expression, and suggest that patient survival is associated with MGMT methylation status.

KW - Gliosarcoma

KW - Immunohistochemistry

KW - Methylation-specific PCR

KW - O -methylguanine-DNA methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=79952184256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952184256&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0267-9

DO - 10.1007/s11060-010-0267-9

M3 - Article

C2 - 20556478

AN - SCOPUS:79952184256

VL - 101

SP - 477

EP - 486

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -